HWM
BMRN icon

HB Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

HB Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$518K Buy
9,052
+973
+12% +$53.3K ﹤0.01% 1085
2026
Q1 		$456K Buy
8,079
+4,016
+99% +$234K ﹤0.01% 1020
2025
Q4 		$241K Buy
4,063
+16
+0.4% +$871 ﹤0.01% 1251
2025
Q3 		$219K Buy
+4,047
New +$231K ﹤0.01% 1228

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

HB Wealth Management's BMRN Position: Q2 2026 in Review

HB Wealth Management increased its BioMarin Pharmaceuticals (BMRN) stake by 12% in Q2 2026, buying an estimated $53.3K and bringing the position to 9,052 shares worth $518K. The position accounts for ﹤0.01% of the portfolio, ranked #1085.

HB Wealth Management first reported a position in BMRN in Q3 2025 and has held it in 4 quarters since. 562 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • HB Wealth Management held 9,052 shares of BioMarin Pharmaceuticals worth $518K as of Q2 2026.
  • HB Wealth Management bought 973 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $53.3K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of HB Wealth Management's portfolio in Q2 2026, its #1085 holding.
  • HB Wealth Management first reported a position in BioMarin Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 562 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.